Latest information on COVID-19
Support teaching, research, and patient care.
My research relates to issues pertaining to clinical kidney transplantation. We have ongoing studies on the following topics.<br/>1. Renal senescence and kidney transplant, and chronic allograft nephropathy.<br/>2. Living donor safety and response to uninephrectomy.<br/>3. Biomarkers for post-transplant monitoring.
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Protocol Title: Randomized open label study comparing the metabolic control of first Kidney
Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral
as part of a ATG induction, prednisone free and blood monitored Cellcept immunosuppressive
PURPOSE This is a single center medical research study to analyze post-transplant kidney
recipients with pre-existing type 2 diabetes managed according to the recommended American
Diabetes Association (ADA) guidelines. Prograf (Tac) and Neoral (CSA) are the two main
medications to prevent rejection after transplantation. However, they may contribute to
poorer diabetes control. The purpose of the study is to compare the effects of Prograf and
Neoral on the control of Diabetes after kidney transplantation. In addition, all participants
in this study will receive Thymoglobulin (anti-lymphocyte globulin) at the time of
transplantation instead of long term prednisone (steroids).
Stanford is currently not accepting patients for this trial.
For more information, please contact Stephan Busque, MD, 650-498-6189.
View full details